Program directory · National Research Council Canada

Human Health Therapeutics

Department

National Research Council Canada

Program code

BNQ07 (NRC)

Core responsibility

Science and Innovation

In Departmental Plans

2018-19 – 2026-27 · New since an earlier plan

What it does

Through research and development of biotherapeutics, vaccines and technology platforms, the Human Health Therapeutic (HHT) program aims to transform human health outcomes for the benefit of society. HHT primarily serves the needs of small and medium enterprises (SMEs) from the Canadian biopharmaceutical industry, although it is also involved in federal government collaborative research aimed at creating solutions for public health issues affecting the lives of Canadians. HHT serves its clients and collaborators through three main mechanisms: it enters collaborative research agreements to co-develop products and technologies, it provides testing or advisory services that result in different types of information being delivered to the client, and it licenses out off-the-shelf products and technology platforms developed and owned by the program. The program directly improves the R&D and innovation capabilities of SME clients through knowledge and technology transfer while also allowing these companies to advance their biologics and vaccine pipelines by de-risking product development and manufacturing activities. HHT will soon enable the production of clinical trial material for its clients through a state of the art GMP compliant Clinical Trial Manufacturing Facility. All of this is expected to lead clients to submit for regulatory approvals, launch clinical trials and eventually commercialize novel products. HHT is ultimately expected to help Canadian biopharmaceutical companies become more competitive on the national and global stages, attract new funding and grow to scale in Canada. HHT also has a role to play in coordinating public health research efforts within the federal government so that public good solutions, such as vaccines to combat infectious diseases or therapeutics to treat rare disorders, can be developed and deployed and so that Canada is in a better position to respond to future public health crises.

Source: the department's Program Inventory, via GC InfoBase.

History and lineage

First appears in GC InfoBase's actual spending by program in 2018-19. The data does not record when a program was created; it may be older than its first appearance here, which is limited by the sources (program spending starts in 2010-11, Departmental Plans in 2018-19).

No earlier or later program in the same department has a similar name.

Significant changes in scope and budget

Success criteria

The program's indicators from its department's Departmental Results Framework: the target set in each year's plan, and the result reported the following year. Source: GC InfoBase.

Spending and employees: planned against actual

Spending

Employees (FTEs)

Planned spending, plan by plan

Each row is one year's Departmental Plan and its forecast for the next three fiscal years; read a column down to see how the forecast for one year changed. The last row is what was actually spent. Click an amount for its source. Biggest changes in federal spending plans

Actual spending is from Departmental Results Reports and the Public Accounts, as published in GC InfoBase. FTEs are full-time equivalents.